Xtandi- The Real Potential and the Astellas Part!

Xtandi- The Real Potential and the Astellas Part!
Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to treat prostate cancer as an ideal antiandrogen therapy (includes positive expectation from interim analysis of PREVAIL expected at ESMO-13/ early 4Q 2013 study in pre-chemo setting) has recently resulted in a rally in Astellas’ price. Although, the clinical profile of Xtandi (steroid free regimen, better safety and efficacy than Zytiga) carries potential to compete with Casodex/Zytiga generics post 2016, we think that emerging new candidates (ARN-509, ODM-021, TAK-700) create some threat for Xtandi and the agreement between Astellas and Medivation is not lucrative enough for Astellas. Xtandi’s major sales will come from metastatic pre-chemo setting due to………
Pre-chemo vs. Post chemo Market size: Metastatic Pre chemo market 3 times bigger than post chemo; Zytiga 1Q 2013 sales reveal this basis……

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Details
MP-10438021

19-Apr-2013

12
License